{"id":22336,"date":"2019-12-19T09:41:40","date_gmt":"2019-12-19T08:41:40","guid":{"rendered":"https:\/\/qlinea.com\/board-of-directors\/"},"modified":"2026-05-28T08:44:04","modified_gmt":"2026-05-28T06:44:04","slug":"board-of-directors","status":"publish","type":"page","link":"https:\/\/qlinea.com\/us\/investor-relations\/corporate-governance\/board-of-directors\/","title":{"rendered":"Board of Directors"},"content":{"rendered":"
\r\n
\r\n
\r\n

Board of Directors<\/h1>\r\n

Q-linea\u2019s BoD consist of a combination of entrepreneurs, inventors and industrial experienced persons representing the major owners of the company, and providing active support to the management.<\/p>\n

Current holdings.<\/p>\n<\/h3>\r\n <\/div>\r\n <\/div>\r\n<\/section>\r\n\n\n\r\n

\r\n
\r\n
\r\n \"\"\r\n <\/div>\r\n
\r\n
\n

Johan Bygge<\/h3>\n

Director since 2025, chairman of the board since 2025<\/strong><\/p>\n

Johan Bygge has a solid background of leading and developing prominent global companies, including as CFO at Investor, Head of Asia for EQT and senior executive at both Electrolux and Husqvarna.<\/p>\n

Born<\/strong>: 1956
\nEducation<\/strong>: MBA from the Stockholm School of Economics.
\nOther current assignments<\/strong>: Johan currently sits on several boards, including: Tredje AP-fonden, Getinge AB (publ), Lantm\u00e4nnen ek f\u00f6r, CapMan Oyj, Scandi Standard AB (publ), and Guard Therapeutics International AB (publ).<\/p>\n

Holdings in the Company<\/strong>: Johan Bygge owns 6,000 shares in the Company and holds 40,000 call options entitling him to acquire shares from the shareholder Investment AB \u00d6resund in four years.<\/p>\n

Johan is independent in relation to the company, its management, and its major shareholders.<\/p>\n<\/div>\n <\/div>\r\n <\/div>\r\n<\/section>\r\n\n\n\r\n

\r\n
\r\n
\r\n \"\"\r\n <\/div>\r\n
\r\n
\n

Mario Gualano<\/h3>\n

Director since 2020, deputy chairman of the board<\/strong><\/p>\n

Mario Gualano\u00a0has more than 25 years of commercial, technical and operational experience in the microbiology and diagnostics industry, including 15 years in international leadership roles with Thermo Fisher Scientific. During his time with Thermo Fisher Scientific, he led Thermo Fisher Scientific\u2019s Specialty Diagnostics Group in APAC and, most recently, was the President of the Microbiology division.<\/p>\n

Born<\/strong>: 1969
\nEducation: <\/strong>PhD in Microbiology and Immunodiagnostics and a MBA from Henley Management College.
\nOther ongoing assignments:<\/strong> Strategic Advisor, BBI Solutions Ltd.<\/p>\n

Holdings in the Company:<\/strong> Mario Gualano does not own any shares in the Company.<\/p>\n

He is independent in relation to the company and its management and in relation to major shareholders.<\/p>\n<\/div>\n <\/div>\r\n <\/div>\r\n<\/section>\r\n\n\n\r\n

\r\n
\r\n
\r\n \"\"\r\n <\/div>\r\n
\r\n
\n

Sebastian Backlund<\/h3>\n

Director since 2025<\/strong><\/p>\n

Sebastian Backlund is currently employed as an investment manager at Investment AB \u00d6resund and is expected to contribute to the work of the board and the company with his strong knowledge of financial and commercial analysis, internal structural and process improvement, capital markets, as well as M&A experience from his previous employers: MedCap AB (publ) and EY Corporate Finance.<\/p>\n

Born<\/strong>: 1990
\nEducation<\/strong>: MSc in Finance, School of Business, Economics and Law, University of Gothenburg. BSc in Economics, Francis Marion University, USA.
\nOther current assignments<\/strong>: Sebastian is a member of the board of Scandi Standard AB.<\/p>\n

Holdings in the Company<\/strong>: Sebastian Backlund owns, directly and indirectly, 150,000 shares in the Company.<\/p>\n

Sebastian is independent in relation to the company and its management, but dependent in relation to the company\u2019s major shareholder (Investment AB \u00d6resund).<\/p>\n<\/div>\n <\/div>\r\n <\/div>\r\n<\/section>\r\n\n\n\r\n

\r\n
\r\n
\r\n \"\"\r\n <\/div>\r\n
\r\n
\n
\n

Erika Kjellberg Eriksson<\/h3>\n

Director since 2012, chairman of the board <\/strong>between 2018 \u2013 2025<\/strong><\/p>\n<\/div>\n

\n

Erika Kjellberg Eriksson has held board assignments and senior positions in pharmaceutical, biotech and medtech companies for more than 25 years. She has extensive experience from working in both listed and unlisted companies and vast board experience.<\/p>\n

Born<\/strong>: 1962
\nEducation<\/strong>: BSc in Economics, Uppsala University (1985).
\nOther current assignments<\/strong>: Erika Kjellberg Eriksson is CEO of Nexttobe AB, chairman of the board of directors of Linum AB, Brixton Medical AB, Lumina Adhesives AB, Lokon Pharma AB, and Tanea Medical AB, Director of Findolon AB.<\/p>\n

Holdings in the Company<\/strong>: Erika Kjellberg Eriksson owns 45,597 shares.<\/p>\n

She is independent in relation to the company and its management, but not in relation to major shareholders.<\/p>\n<\/div>\n<\/div>\n <\/div>\r\n <\/div>\r\n<\/section>\r\n\n\n\r\n

\r\n
\r\n
\r\n \"\"\r\n <\/div>\r\n
\r\n

Jonas Jarvius<\/h3>\n

Director since 2024<\/strong><\/p>\n

Jonas Jarvius has over 20 years of experience in research and development in molecular medicine and molecular biology detection. He has co-founded several companies and is one of the founders of Q-linea. He served as CEO of the company from 2008 to 2024. For many years, he has been active in leading positions in various biotech companies and has been responsible for projects concerning e.g. molecular identification for security applications as well as manufacturing and development of medical devices. He also has experience in certification according to ISO-13485, a standard for quality management intended for medical devices. He has also been involved in a number of biotech startups.<\/p>\n

Born<\/strong>: 1971
\nEducation: <\/strong>PhD in Molecular Medicine and a Master’s degree in Medicine, Uppsala University.
\nOther ongoing assignments:<\/strong> President, CEO and Director of Bifrost Biosystems, Inc. Member of the board of directors of Umbrella Science AB.<\/p>\n

Holdings in the Company:<\/strong> Jonas Jarvius owns 18,419 shares in the Company.<\/p>\n

He is dependent in relation to the company and its management and independent in relation to major shareholders.<\/span><\/p>\n <\/div>\r\n <\/div>\r\n<\/section>\r\n\n\n\r\n

\r\n
\r\n
\r\n \"\"\r\n <\/div>\r\n
\r\n

\u00d6ystein Engebretsen<\/span><\/h3>\n

Director since 2026<\/strong><\/p>\n

\u00d6ystein Engebretsen has extensive board experience and long-standing experience from the finance and investment industry.<\/p>\n

Born<\/strong>: 1980
\nEducation:<\/strong>\u00d6ystein Engebretsen holds a Master of Science in Business with a major in Finance from BI Norwegian School of Management, Sandvika\/Oslo.<\/p>\n

Holdings in the Company:<\/strong> \u00d6ystein Engebretsen own directly and indirectly, a total of 106,450 shares in the Company.<\/span><\/p>\n

\u00d6ystein Engebretsen is independent in relation to the Company and its management but not independent in relation to the Company’s major shareholders.<\/span><\/p>\n <\/div>\r\n <\/div>\r\n<\/section>\r\n\n\n\r\n

\r\n
\r\n
\r\n \"\"\r\n <\/div>\r\n
\r\n

Kari E. Krogstad<\/span><\/h3>\n

Director since 2026<\/strong><\/p>\n

Kari E. Krogstad assumed the position of CEO of Medistim in September 2009. She has more than 30 years of experience from the biomedical industry and has held commercial leadership roles in the pharmaceutical, biotechnology and medical technology sectors. Before joining Medistim, she worked for 11 years at Dynal, where, following Invitrogen’s acquisition in 2005, she also led Invitrogen Dynal in the role of General Manager.<\/span><\/p>\n

Born<\/strong>: 1964
\nEducation:<\/strong>Kari E. Krogstad holds a Master of Science (M.Sc.) in molecular biology from the University of Oslo and a business degree from IHM Business School.
\nOther ongoing assignments:<\/strong> CEO Medistim<\/span><\/p>\n

Holdings in the Company:<\/strong> Kari E. Krogstad holds no shares in the Company.<\/span><\/p>\n

Kari E. Krogstad is independent in relation to the Company and its management and in relation to major shareholders.<\/span><\/p>\n <\/div>\r\n <\/div>\r\n<\/section>\r\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":22348,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-22336","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/pages\/22336","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/comments?post=22336"}],"version-history":[{"count":9,"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/pages\/22336\/revisions"}],"predecessor-version":[{"id":30266,"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/pages\/22336\/revisions\/30266"}],"up":[{"embeddable":true,"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/pages\/22348"}],"wp:attachment":[{"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/media?parent=22336"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}